Prostate Cancer Survival
Prostate Cancer Survival - http://www.medical-research-study-dir...
Life after Prostate Cancer surgery:
This is video #26 in the series on One prostate cancer patient's views & opinions after prostate cancer surgery.
This video, #26, was made two years after my robotic radical prostatectomy. In this type of prostate cancer surgery the surgeon moves the robotic arm while sitting at a computer monitor near the operating table. The nerve bundles on either side of the prostate are responsible for erections and if they appear to be cancer-free, the surgeon usually will not remove them. This modified operation is called a nerve-sparing radical prostatectomy.
After my prostate cancer surgery, the pathology report on the removed prostate gland was good, but my surgeon always has the fatty tissue that is around the prostate gland analyzed (most doctors do NOT have this done), it turned out in my case, that prostate cancer was found in the lymph nodes of this tissue. So, unfortunately for me, I ended up with stage four prostate cancer.
Again, in my case, the recommended course of action was hormone therapy, not to kill the cancer (there is no cure for prostate cancer) but to slow its progress. Testosterone deprivation therapy is also known as androgen deprivation therapy (ADT). Testosterone increases beyond the castrate level have been shown to increase the rate of spread of an existing prostate cancer.
Usually, at some point, the prostate cancer is no longer affected by the hormone testosterone deprivation therapy. Yes, it seems (from my limited research) ultimately, most men will develop prostate cancer that is refractory to all hormonal manipulations. This is termed androgen-independent prostate cancer. There is no consensus as to whether LHRH agonists should be withdrawn at this time. The rationale for withdrawing the LHRH agonist would be to improve quality of life and possibly diminish any osteoporosis, muscle wasting, anemia, and depression that are usually associated with the LHRH agonist.
Androgen deprivation therapy (ADT) in the management of prostate cancer is highly controversial but, ADT is universally accepted as first-line treatment of symptomatic metastatic prostate cancer. Today, the benefits of maximum androgen blockade (MAB), the management of adverse events associated with ADT, the role of intermittent ADT, and the benefits of secondary hormonal therapies remain unresolved.
To view the entire on-going prostate cancer video series, please visit:
http://www.medical-research-study-dir...
For good search engine optimization ideas, visit a great SEO blog at:
http://www.websitetrafficbuilders.com...